☆ 4.7 Article

Daratumumab Interferes with Allogeneic Crossmatch Impacting Immunological Assessment in Solid Organ Transplantation

JOURNAL OF CLINICAL MEDICINE (2022)

Related references

Note: Only part of the references are listed.

Review Biotechnology & Applied Microbiology

Anti CD38 monoclonal antibodies for multiple myeloma treatment

Alessandro Gozzetti et al.

Summary: CD38 is a glycoprotein expressed on multiple myeloma cells, which has sparked interest in new drug development. Monoclonal antibodies targeting CD38 have pleiotropic mechanisms of action, revolutionizing MM therapy by increasing treatment depth.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2022)

Add to Collection

Article Immunology

CD38 Antibody Daratumumab for the Treatment of Chronic Active Antibody-mediated Kidney Allograft Rejection

Konstantin Doberer et al.

Summary: The study highlights the potential of targeting CD38 for plasma cell and NK cell depletion in treating AMR. The use of daratumumab in a kidney allograft recipient with chronic active AMR led to significant improvements in immune cell counts, donor-specific antibody levels, and rejection-related gene expression patterns. This innovative treatment concept shows promise for future trials in organ transplantation research.

TRANSPLANTATION (2021)

Add to Collection

Article Immunology

Impact of rituximab on the T-cell flow cytometric crossmatch

Sam Arul Doss et al.

Summary: Rituximab, commonly used in ABO-incompatible renal transplants, was found to have an impact on T-cell flow cytometric crossmatch (T-FCXM) where "T-cell tailing" phenomenon was observed but cleared with pronase treatment. This phenomenon led to weak positive results in T-FCMX ratios, however, the absence of donor-specific antibodies in recipients suggests it is a false positive finding. The structural homology of Fc receptors on activated T-cells to CD20 may provide insight into a novel mechanism of action of rituximab.

TRANSPLANT IMMUNOLOGY (2021)

Add to Collection

Editorial Material Immunology

Physical crossmatching vs virtual crossmatching: The end of an era? or Why give up a good thing?

H. Clifford Sullivan et al.

HUMAN IMMUNOLOGY (2020)

Add to Collection

Article Urology & Nephrology

Daratumumab in Sensitized Kidney Transplantation: Potentials and Limitations of Experimental and Clinical Use

Jean Kwun et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2019)

Add to Collection

Review Immunology

Of Cells and Microparticles: Assets and Liabilities of HLA Antibody Detection

Robert S. Liwski et al.

TRANSPLANTATION (2018)

Add to Collection

Article Pharmacology & Pharmacy

Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment

Pamela L. Clemens et al.

CLINICAL PHARMACOKINETICS (2017)

Add to Collection

Article Biotechnology & Applied Microbiology

Daratumumab for the treatment of multiple myeloma

Cyrille Touzeau et al.

EXPERT OPINION ON BIOLOGICAL THERAPY (2017)

Add to Collection

Article Hematology

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

Jakub Krejcik et al.

BLOOD (2016)

Add to Collection

Article Urology & Nephrology

Trends in Survival and Renal Recovery in Patients with Multiple Myeloma or Light-Chain Amyloidosis on Chronic Dialysis

Alexandre Decourt et al.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)

Add to Collection

Article Immunology

Variable HLA expression on deceased donor lymphocytes: Not all crossmatches are created equal

Jessica L. Badders et al.

HUMAN IMMUNOLOGY (2015)

Add to Collection

Article Hematology

Resolving the daratumumab interference with blood compatibility testing

Claudia I. Chapuy et al.

TRANSFUSION (2015)

Add to Collection

Review Oncology

Therapeutic advancements in multiple myeloma

Alessandro Gozzetti et al.

FRONTIERS IN ONCOLOGY (2014)

Add to Collection

Review Urology & Nephrology

Kidney Disease and Multiple Myeloma

Eliot C. Heher et al.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2013)

Add to Collection

Article Immunology

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

Michel de Weers et al.

JOURNAL OF IMMUNOLOGY (2011)

Add to Collection

Article Surgery

Pretransplant risk assessment in renal allograft recipients using virtual crossmatching

D. Bielmann et al.

AMERICAN JOURNAL OF TRANSPLANTATION (2007)

Add to Collection

Review Oncology

Human CD38: a (r)evolutionary story of enzymes and receptors

S Deaglio et al.

LEUKEMIA RESEARCH (2001)

Add to Collection

© Peeref 2019-2024. All rights reserved.